Ixico (IXI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

11.20p
   
  • Change Today:
    -0.30p
  • 52 Week High: 13.00p
  • 52 Week Low: 7.75p
  • Currency: UK Pounds
  • Shares Issued: 92.67m
  • Volume: 19,793
  • Market Cap: £10.38m
  • Beta: 0.04

Latest ShareCast News

Ixico secures two clinical trial contracts worth £1.3m

By Josh White

Date: Tuesday 12 Aug 2025

(Sharecast News) - Ixico has secured two new clinical trial contracts in neurological disorders with a combined value of about £1.3m, it announced on Friday, extending its presence in both Alzheimer's disease and rare central nervous system conditions.

Ixico flags better-than-expected full-year revenue

By Josh White

Date: Thursday 17 Jul 2025

(Sharecast News) - Ixico said in an update on Thursday that it expects revenue for the financial year ending 30 September to be at least £6.3m, ahead of market expectations and representing a 9% increase from the prior year.

Ixico upbeat on breakthrough with AI imaging platform

By Josh White

Date: Wednesday 12 Feb 2025

(Sharecast News) - Ixico announced further validation of its AI-driven imaging platform IXIQ.Ai in Huntington's disease (HD) research on Wednesday, through its collaboration with the Huntington's Disease Imaging Harmonisation (HD-IH) consortium.

Ixico secures new contract with US-based client 10-Dec-2024 ShareCast
Ixico raises expectations on new contract wins 14-Aug-2024 ShareCast
Ixico reports progress in Huntington's disease i... 29-Jul-2024 ShareCast
Ixico wins £1m research contract 19-Jun-2024 ShareCast
Ixico inks supply agreement with LMI 15-Apr-2024 ShareCast
Ixico warns on 2024 revenue amid contract delays 13-Mar-2024 ShareCast
Ixico CEO to step down by end of year 12-Jan-2024 ShareCast
Ixico full-year earnings could slightly exceed f... 29-Sep-2023 ShareCast
Ixico awarded new £2m, four-year contract 14-Jun-2023 ShareCast
Ixico set to report first-half loss as legacy is... 10-May-2023 ShareCast
Ixico wins £700,000 contract with biotech company 10-Mar-2023 ShareCast
Ixico awarded two-year MRI imaging contract 09-Dec-2022 ShareCast
Full-year revenue set to fall for Ixico 25-Oct-2022 ShareCast
Ixico to extend work on Huntington's disease trial 14-Jun-2022 ShareCast
Ixico joins Huntington's disease research consor... 10-May-2022 ShareCast
Ixico confident after first-half revenues fall 25-Apr-2022 ShareCast
Ixico selected for Huntington's disease detectio... 21-Apr-2022 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Ixico Market Data

Currency UK Pounds
Share Price 11.20p
Change Today -0.30p
% Change -2.61 %
52 Week High 13.00p
52 Week Low 7.75p
Volume 19,793
Shares Issued 92.67m
Market Cap £10.38m
Beta 0.04

Ixico Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
24.04% below the market average24.04% below the market average24.04% below the market average24.04% below the market average24.04% below the market average
65.85% above the sector average65.85% above the sector average65.85% above the sector average65.85% above the sector average65.85% above the sector average
Price Trend
18.00% above the market average18.00% above the market average18.00% above the market average18.00% above the market average18.00% above the market average
31.82% above the sector average31.82% above the sector average31.82% above the sector average31.82% above the sector average31.82% above the sector average
Income Not Available
Growth
78.76% below the market average78.76% below the market average78.76% below the market average78.76% below the market average78.76% below the market average
93.1% below the sector average93.1% below the sector average93.1% below the sector average93.1% below the sector average93.1% below the sector average

Ixico Dividends

No dividends found

Trades for 16-Sep-2025

Time Volume / Share Price
10:01 3,500 @ 11.06p
09:59 500 @ 11.12p
09:59 1,000 @ 11.12p
08:39 10,000 @ 11.50p
08:00 10 @ 12.00p

Ixico Key Personnel

CEO Giulio Cerroni
CEO Bram Goorden

Top of Page